Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Michigan Breast Specialists-Warren
mi
from
Warren, MI
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Michigan Breast Specialists-Warren
mi
from
Warren, MI
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Mary's Oncology/Hematology Associates of West Branch
mi
from
West Branch, MI
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Mary's Oncology/Hematology Associates of West Branch
mi
from
West Branch, MI
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Huron Gastroenterology PC
mi
from
Ypsilanti, MI
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Huron Gastroenterology PC
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
IHA Hematology Oncology Consultants-Ann Arbor
mi
from
Ypsilanti, MI
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
IHA Hematology Oncology Consultants-Ann Arbor
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Medical Center-Baker City
mi
from
Baker City, OR
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Medical Center-Baker City
mi
from
Baker City, OR
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Medical Center-Ontario
mi
from
Ontario, OR
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Medical Center-Ontario
mi
from
Ontario, OR
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital-Cedar Crest
mi
from
Allentown, PA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital-Cedar Crest
mi
from
Allentown, PA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital - Muhlenberg
mi
from
Bethlehem, PA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital - Muhlenberg
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare-Bloomington
mi
from
Bloomington, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare-Bloomington
mi
from
Bloomington, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare - Canton
mi
from
Canton, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare - Canton
mi
from
Canton, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Memorial Hospital of Carbondale
mi
from
Carbondale, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Memorial Hospital of Carbondale
mi
from
Carbondale, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare - Carthage
mi
from
Carthage, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare - Carthage
mi
from
Carthage, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Centralia Oncology Clinic
mi
from
Centralia, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Centralia Oncology Clinic
mi
from
Centralia, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare - Eureka
mi
from
Eureka, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare - Eureka
mi
from
Eureka, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare - Galesburg
mi
from
Galesburg, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare - Galesburg
mi
from
Galesburg, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare - Kewanee Clinic
mi
from
Kewanee, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare - Kewanee Clinic
mi
from
Kewanee, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare - Macomb
mi
from
Macomb, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare - Macomb
mi
from
Macomb, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare-Ottawa Clinic
mi
from
Ottawa, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare-Ottawa Clinic
mi
from
Ottawa, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare - Pekin
mi
from
Pekin, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare - Pekin
mi
from
Pekin, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
mi
from
Peoria, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare - Peru
mi
from
Peru, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare - Peru
mi
from
Peru, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare - Princeton
mi
from
Princeton, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare - Princeton
mi
from
Princeton, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Memorial Medical Center
mi
from
Springfield, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Memorial Medical Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Cancer Care Specialists of Illinois-Swansea
mi
from
Swansea, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Cancer Care Specialists of Illinois-Swansea
mi
from
Swansea, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Siouxland Regional Cancer Center
mi
from
Sioux City, IA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Siouxland Regional Cancer Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Sparrow Hospital
mi
from
Lansing, MI
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sparrow Hospital
mi
from
Lansing, MI
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Francis Medical Center
mi
from
Cape Girardeau, MO
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Francis Medical Center
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Southeast Cancer Center
mi
from
Cape Girardeau, MO
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Southeast Cancer Center
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Missouri Baptist Sullivan Hospital
mi
from
Sullivan, MO
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Missouri Baptist Sullivan Hospital
mi
from
Sullivan, MO
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Missouri Baptist Outpatient Center-Sunset Hills
mi
from
Sunset Hills, MO
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Missouri Baptist Outpatient Center-Sunset Hills
mi
from
Sunset Hills, MO
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
SIH Cancer Institute
mi
from
Carterville, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
SIH Cancer Institute
mi
from
Carterville, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Crossroads Cancer Center
mi
from
Effingham, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Crossroads Cancer Center
mi
from
Effingham, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Western Illinois Cancer Treatment Center
mi
from
Galesburg, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Western Illinois Cancer Treatment Center
mi
from
Galesburg, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
mi
from
Pekin, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
mi
from
Pekin, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Valley Radiation Oncology
mi
from
Peru, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Valley Radiation Oncology
mi
from
Peru, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Springfield Clinic
mi
from
Springfield, IL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Springfield Clinic
mi
from
Springfield, IL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Parkland Health Center-Bonne Terre
mi
from
Bonne Terre, MO
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Parkland Health Center-Bonne Terre
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Missouri Baptist Medical Center
mi
from
Saint Louis, MO
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Missouri Baptist Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Sainte Genevieve County Memorial Hospital
mi
from
Sainte Genevieve, MO
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sainte Genevieve County Memorial Hospital
mi
from
Sainte Genevieve, MO
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Sanford Bismarck Medical Center
mi
from
Bismarck, ND
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sanford Bismarck Medical Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Sanford Cancer Center-Oncology Clinic
mi
from
Sioux Falls, SD
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sanford Cancer Center-Oncology Clinic
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Sanford USD Medical Center - Sioux Falls
mi
from
Sioux Falls, SD
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sanford USD Medical Center - Sioux Falls
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
mi
from
Baltimore, MD
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials